79 related articles for article (PubMed ID: 8820459)
1. DaunoXome shows promise as breast cancer treatment.
Oncology (Williston Park); 1996 Mar; 10(3):425. PubMed ID: 8820459
[No Abstract] [Full Text] [Related]
2. [Administration of liposomal preparation of DaunoXome for breast cancer in patients with poor prognosis].
Darskaia EI; Zubarovskaia LS; Afanas'ev BV
Vopr Onkol; 1999; 45(4):440-4. PubMed ID: 10532108
[TBL] [Abstract][Full Text] [Related]
3. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer.
O'Byrne KJ; Thomas AL; Sharma RA; DeCatris M; Shields F; Beare S; Steward WP
Br J Cancer; 2002 Jul; 87(1):15-20. PubMed ID: 12085249
[TBL] [Abstract][Full Text] [Related]
4. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
[TBL] [Abstract][Full Text] [Related]
5. Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors.
Boiardi A; Pozzi A; Salmaggi A; Eoli M; Zucchetti M; Silvani A
Cancer Chemother Pharmacol; 1999; 43(2):178-9. PubMed ID: 9923826
[No Abstract] [Full Text] [Related]
6. Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma.
Richardson DS; Kelsey SM; Johnson SA; Tighe M; Cavenagh JD; Newland AC
Invest New Drugs; 1997; 15(3):247-53. PubMed ID: 9387047
[TBL] [Abstract][Full Text] [Related]
7. Kaposi's sarcoma: DaunoXome approved.
AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
[TBL] [Abstract][Full Text] [Related]
8. Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
Dobashi N; Usui N; Yano S; Yahagi Y; Takei Y; Sugiyama K; Takahara S; Ogasawara Y; Yamaguchi Y; Saito T; Yokoyama H; Aiba K
Jpn J Clin Oncol; 2011 Jun; 41(6):820-4. PubMed ID: 21415001
[TBL] [Abstract][Full Text] [Related]
9. [The therapeutic efficacy and toxicity of the liposomal form of daunorubicin (Daunoxome) in lymphosarcoma patients].
Medvedev PV; Nikitin EA; Pivnik AV
Ter Arkh; 2000; 72(7):38-42. PubMed ID: 10983319
[TBL] [Abstract][Full Text] [Related]
10. Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia.
Piccaluga PP; Visani G; Martinelli G; Isidori A; Malagola M; Rondoni M; Baccarani M; Tura S
Leukemia; 2002 Sep; 16(9):1880-1. PubMed ID: 12200714
[No Abstract] [Full Text] [Related]
11. [Results of a phase I-II clinical trial of Emoxyl, a novel antineoplastic anthracycline].
Korman DB; Mikaélian SG; Boronovskaia LE; Maslova IA
Vopr Onkol; 2004; 50(2):202-7. PubMed ID: 15176224
[TBL] [Abstract][Full Text] [Related]
12. Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes.
Yeo W; Chan KK; Mukwaya G; Ross M; Leung WT; Ho S; Chan AT; Johnson PJ
Cancer Chemother Pharmacol; 1999; 44(2):124-30. PubMed ID: 10412946
[TBL] [Abstract][Full Text] [Related]
13. NeXstar Pharmaceuticals lauches DaunoXome.
J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):52. PubMed ID: 11363700
[TBL] [Abstract][Full Text] [Related]
14. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M
Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004
[TBL] [Abstract][Full Text] [Related]
15. [Trial of chemotherapy with a new antimitotic derivative].
Chauvergne J
Nouv Presse Med; 1973 Mar; 2(9):581. PubMed ID: 4703337
[No Abstract] [Full Text] [Related]
16. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
Fumagalli L; Zucchetti M; Parisi I; Viganò MG; Zecca B; Careddu A; D'Incalci M; Lazzarin A
Cancer Chemother Pharmacol; 2000; 45(6):495-501. PubMed ID: 10854138
[TBL] [Abstract][Full Text] [Related]
17. Unforeseen Severe Cardiotoxicity Associated With Daunorubicin Chemotherapy Even at a Dose Previously Thought to Be Safe: A Case Report.
Juan MCY; Jones RT; Thabolingam RC
Am J Ther; 2017; 24(4):e503-e504. PubMed ID: 27272204
[No Abstract] [Full Text] [Related]
18. Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors.
Lippens RJ
Pediatr Hematol Oncol; 1999; 16(2):131-9. PubMed ID: 10100273
[TBL] [Abstract][Full Text] [Related]
19. DaunoXome offers KS treatment alternative.
AIDS Alert; 1996 Jun; 11(6):67-8. PubMed ID: 11363544
[TBL] [Abstract][Full Text] [Related]
20. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma.
White RM
AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461
[No Abstract] [Full Text] [Related]
[Next] [New Search]
